Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Marinus Pharmaceuticals excels in Q4 with ZTALMY sales surge

Marinus Pharmaceuticals' Q4 2022 performance reflects strong demand for ZTALMY and progress in clinical pipeline development.
The company's strengths lie in successful product launches, intellectual property advancements, and a positive outlook for 2023.
Challenges include careful decision-making processes and efforts to expand patient reach and market awareness.
Opportunities for Marinus include global market expansion, increased disease diagnosis rates, and innovative drug development strategies.

Marinus Pharmaceuticals reports steady growth and strategic expansion opportunities

Marinus Pharmaceuticals demonstrated steady revenue growth and operational progress in advancing clinical programs and expanding market reach.
The company faces challenges in product development, trial management, and market dynamics but is well-positioned to capitalize on growth opportunities.
Strategic initiatives in IP portfolio expansion, market expansion in new regions, and a focus on innovation and patient safety underpin the company's growth trajectory.
CEO's strategic vision, emphasis on market exclusivity, and confidence in franchise longevity signal a strong foundation for future success and market leadership.

Marinus Pharmaceuticals reports robust earnings, faces trial enrollment challenges

Marinus Pharmaceuticals shows strong financial performance and operational resilience in Q2 2023.
The company faces challenges in trial enrollment delays but maintains a focus on innovation and market expansion.
Opportunities lie in product diversification, market growth, and demonstrating the value of their drug portfolio.

Marinus Pharmaceuticals surpasses revenue targets, eyes global expansion opportunities

Marinus Pharmaceuticals demonstrated strong financial performance in Q3 2023, with revenue exceeding expectations and a healthy cash position.
The company's strategic focus on expanding ZTALMY access globally and prioritizing high-value patient populations showcases a promising growth trajectory.
Challenges such as high screening attrition rates and gross to net deductions are being addressed, while opportunities in patient population expansion and program pricing present avenues for future success.
Overall, Marinus Pharmaceuticals is well-positioned for continued growth and innovation in the pharmaceutical market, supported by ongoing clinical trials and strategic initiatives.

Marinus Pharmaceuticals beats revenue targets, eyes blockbuster franchise growth

Marinus Pharmaceuticals showed strong performance in Q4 2023 with revenue exceeding guidance
Financially, the company is well-positioned with a healthy cash balance and controlled operating expenses
Challenges include increased R&D expenses and cash burn, but opportunities lie in revenue growth and market readiness
Excitement surrounds the progress of IV ganaxolone trials and potential blockbuster franchise plans

Marinus Pharmaceuticals excels with ZTALMY profitability and global expansion

Marinus Pharmaceuticals has shown strong performance with ZTALMY and the TSC trial, supported by strategic financial actions and operational advancements.
While facing challenges in maintaining growth momentum and patient acquisition, the company is well-positioned for global expansion and profitability post-TSC launch.
Opportunities lie in expanding market access, enhancing manufacturing capabilities, and preparing for a successful launch in key regions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.

Marinus Pharmaceuticals (MRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Marinus Pharmaceuticals, Inc. (NasdaqGM: MRNS) to Immedica Pharma AB. Under the terms of the proposed transaction, shareholders of Marinus will receive $0.55 in cash for each share of Marinus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or w.

MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Marinus (Nasdaq: MRNS) for possible breaches of fiduciary duty and other violations of law in its transaction with the Immedica. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Marinus shareholders will receive $0.55 per share. Marinus insiders will receive substantial benefits as pa.

Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) to Immedica Pharma AB for $0.55 per share is fair to Marinus shareholders. Halper Sadeh encourages Marinus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Marinus an.

MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders

STOCKHOLM & RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger. The acquisition complements and further strengthens Immedica's gl.

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.61 per share a year ago.

Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2024. “We are pleased to see continued commercial growth of ZTALMY with more than 200 patients active on therapy and a steady increase in demand,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of.

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex (TSC) in children and adults did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency. While reductions in seizure frequency fav.

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today presented new data from the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) at the Neurocritical Care Society (NCS) Annual Meeting. Topline data demonstrating that the trial met one of two co-primary endpoints were reported in June.

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting

Amprius Technologies Inc

Comstock Mining

Micro-cap stocks can come in many shapes and sizes. Some might be once successful firms that lost their way and are looking to recover their prior glory.

3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced it has added to its intellectual property (IP) estate with a new patent issued by the United States Patent and Trademark Office (USPTO) for ZTALMY® (ganaxolone) oral titration regimens covering the treatment of a range of epilepsy disorders, including CDKL5 deficiency disorder, tuberous sclerosis.

Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that additional data from the Phase 3 RAISE trial in refractory status epilepticus and retrospective claims-based data from patients with status epilepticus will be presented at the upcoming Neurocritical Care Society (NCS) 22nd Annual Meeting, being held October 14-17 in San Diego, California. Pr.

Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to one new employee. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 9,800 shares of its common stock (the “Common Stock”) as inducements material to the employees entering.

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Marinus Pharmaceuticals MRNS is a micro-cap pharmaceutical stock with multiple Wall Street analysts seeing significant upside. Both Oppenheimer and Cantor Fitzgerald recently issued or reiterated massive price targets for the company.

Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today is hosting an Investor and Analyst Day and will present an in-depth review of the Company's development program for ZTALMY® (ganaxolone) oral suspension CV in tuberous sclerosis complex (TSC) ahead of the Phase 3 TrustTSC trial topline data readout anticipated in the first half of the fourth quarter of 2024.

Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced agenda topics and speakers for its upcoming Investor & Analyst Day on Friday, September 20 from 9:00 a.m. to 12:00 p.m. ET in New York. The event will feature presentations from Marinus' leadership and key opinion leaders (KOLs) with a focus on the development program and commercial launch pre.

Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 10:20 a.m. ET. A link to the event can be accessed on the Investors and Media page of Marinus' website at ir.marinuspharma.com/events-and-presentations. A replay.

Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host an Investor and Analyst Day on Friday, September 20 from 9:00 a.m. to 12:00 p.m. Eastern Time in New York and via webcast. The event will feature presentations from Marinus management and key opinion leaders with a focus on the Company's development program for ZTALMY® (ganaxolone) oral suspension CV in.

Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Sonya Weigle - Chief People and Investor Relations Officer Scott Braunstein - Chairman and Chief Executive Officer Lisa Lejuwaan - Senior Vice President and Business Unit Lead, Rare Genetic Epilepsy Joseph Hulihan - Chief Medical Officer Steven Pfanstiel - Chief Financial Officer and Chief Operating Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Joseph Thome - TD Cowen Andrew Tsai - Jefferies Douglas Tsao - H.C. Wainwright Marc Goodman - Leerink Operator Greetings and welcome to Marinus Pharmaceuticals' Second Quarter Financial Results and Business Update Call.

Marinus Pharmaceuticals, Inc. (MRNS) Q2 2024 Earnings Call Transcript

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.61 per share a year ago.

Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Misses Revenue Estimates

Mind Medicine MindMed

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense, a leading provider of Modular Open Systems Approach (MOSA) products and mission solutions, announced their team to compete for the U.S. Army's CMOSS Mounted Form Factor (CMFF) program. Led by Pacific Defense, the CMFF team includes state-of-the-art industry technology leaders Thales Defense & Security Inc., BAE, Regal Technology Partners, Palantir and STC, an Arcfield Company. “Our company is purpose-built to drive the open-systems chang.

Pacific Defense Announces US Army CMFF Program Team

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the second quarter ended June 30, 2024. “Since launching ZTALMY in the U.S. two years ago, we have seen significant growth and adoption with strong revenue for the second quarter, underscoring the appreciation physicians, patients and caregivers have fo.

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Invited To Participate In The Marinus Pharmaceuticals Inc Fraud Investigation With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

MRNS Investors Have Opportunity To Join Marinus Pharmaceuticals Inc Fraud Investigation With The Schall Law Firm

Lyell Immunopharma

Ocular Therapeutix

For investors, one of the most attractive aspects of biotech stocks is their ability to increase in value in a short period of time quickly. After all, it only takes one major breakthrough in clinical trials or a Food and Drug Administration approval to rush a stock into the headlines rapidly.

News for Marinus Pharmaceuticals Stock (MRNS)